Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

NCT02191059 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

NCT01040780 ·Status: COMPLETED ·Phase: PHASE3

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112 ·Status: COMPLETED ·Phase: PHASE1

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

NCT05055947 ·Status: COMPLETED

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 ·Status: RECRUITING ·Phase: PHASE1

D-0316 First Time in Patients Ascending Dose Study

NCT03452150 ·Status: COMPLETED ·Phase: PHASE1

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

NCT01929200 ·Status: UNKNOWN ·Phase: PHASE2

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

NCT03434418 ·Status: COMPLETED ·Phase: PHASE2

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

NCT00059722 ·Status: COMPLETED ·Phase: PHASE2

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

NCT00569114 ·Status: COMPLETED ·Phase: PHASE1

Real World Data on Gi(l)Otrif® Dose Adjustment

NCT02751879 ·Status: COMPLETED

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

NCT03260491 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

NCT05271916 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

NCT01720901 ·Status: SUSPENDED ·Phase: PHASE4

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

NCT05756153 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

NCT01039948 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

NCT04031898 ·Status: COMPLETED

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

NCT02590952 ·Status: COMPLETED ·Phase: PHASE1

Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

NCT00567359 ·Status: COMPLETED ·Phase: PHASE2

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

NCT02191891 ·Status: COMPLETED ·Phase: PHASE1